At the University of Oklahoma, researchers have discovered that obesity fundamentally rewires how early breast cancer becomes dangerous—and the mechanism is far more complex than anyone expected. The finding, published in The American Journal of Pathology, reveals that cancer cells in women with obesity don't follow the same playbook as those in women without obesity, suggesting that the disease's pathway to invasion depends heavily on the metabolic environment surrounding the tumor.
Obesity has long been known as a risk factor for invasive breast cancer, but the precise biological mechanism remained mysterious. Now, Bethany Hannafon and her team at the OU College of Medicine have begun to crack it open. In women without obesity, early breast cancers show the familiar hallmarks of progression: rapid cell division and increased ability to invade nearby tissue. But in women with obesity, the researchers observed an entirely different set of changes unfolding at the cellular level.
The tumor microenvironment becomes inflamed, attracting immune cells that paradoxically advance tumor growth rather than fight it. The cancer cells themselves gain an enhanced ability to survive stress. Metabolic pathways shift—the cells learn to extract and use nutrients more efficiently for energy and growth. As Hannafon explains, "The changes that the cancer cells are undergoing are allowing them to survive and thrive."
What makes this finding particularly significant is the discovery of cooperation between different cell types. Epithelial cells don't act alone; they co-opt surrounding cells to build an ecosystem that feeds cancer progression. Elizabeth Wellberg, co-lead author and assistant professor in the Department of Pathology, frames the puzzle this way: "In women with obesity, there is cooperation between all the cell types, not just the cancer cells, which helps an early pre-cancer to become an invasive breast cancer."
The research team also identified elevated levels of an enzyme called Sulfatase 2 (SULF2) in tumor cells of women with obesity—a clue that could unlock new treatment targets. Future studies will explore whether drugs or interventions targeting single cell types might interrupt the entire network driving progression toward invasive disease.
This work carries immediate clinical implications. Many women diagnosed with ductal carcinoma in situ (DCIS)—an early, noninvasive form—never develop invasive cancer, yet all receive aggressive treatment: surgery, radiation, and sometimes hormone therapy. About half of DCIS patients do progress to invasive ductal carcinoma, but doctors currently have no reliable way to identify which women are at highest risk. The result is widespread overtreatment. Better predictive tools could spare countless women from unnecessary procedures and side effects.
The stakes are rising. Cole Hladik, the paper's first author, notes a sobering projection: 50 percent of Americans are expected to be obese by 2030. This demographic trend makes understanding obesity's role in cancer progression not just scientifically interesting but public health urgent. While breast cancer survival rates have improved over the past two decades, the number of new invasive diagnoses hasn't declined—underscoring the need for better prevention and early intervention strategies.
The OU team's work opens a door to personalized medicine rooted in metabolic health. Rather than treating all early-stage cancers the same way, doctors might soon be able to assess each patient's individual risk based on obesity status and the molecular signature of their tumor, potentially sparing some women unnecessary treatment while protecting others who need it most.